AAV9-CHRNA1
AAV9-CHRNA1 has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jul 6, 2022: “CHRNA1 induces sarcopenia through neuromuscular synaptic elimination”.
1 paper studies it3 findingsUpdated
- 1 lab in 1 country
- Funders: National Natural Science Foundation of China and 1 more
- Animals1
What did studies of AAV9-CHRNA1 find?
3Studies of AAV9-CHRNA1 measured 3 outcomes; the most studied are skeletal muscle function (1 study), skeletal muscle mass (1) and muscle innervation (1).
Skeletal muscle function
downin rodents1
1 study
Skeletal muscle function
downin rodents1
AAV9-CHRNA1 impairs skeletal muscle function in rodents.
“The function of skeletal muscle also decreased, which was manifested by decreases of compound muscle action potential and muscle contractility.”
Animalsskeletal muscle
CHRNA1 induces sarcopenia through neuromuscular synaptic elimination
Experimental gerontology
Skeletal muscle mass
downin rodents1
1 study
Skeletal muscle mass
downin rodents1
AAV9-CHRNA1 decreases skeletal muscle mass in rodents.
“At the same time, the skeletal muscle mass decreased, as manifested by a decrease in the gastrocnemius mass index and the cross-sectional area of the muscle fibers.”
Animalsskeletal muscle
CHRNA1 induces sarcopenia through neuromuscular synaptic elimination
Experimental gerontology
Muscle innervation
downin rodents1
1 study
Muscle innervation
downin rodents1
AAV9-CHRNA1 decreases muscle innervation in rodents.
“local injection of AAV9-CHRNA1 into the hindlimb muscles decreased the percentage of muscle innervation.”
Animalsskeletal muscle
CHRNA1 induces sarcopenia through neuromuscular synaptic elimination
Experimental gerontology